# Aurélien Marabelle

Source: https://onco.cc/people/aurelien-marabelle/  
OnCo record `aurelien-marabelle` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aurélien Marabelle is the immunotherapy investigator behind the tumour-agnostic pembrolizumab data in MSI-high cancers.

## Summary

Aurélien Marabelle is Clinical Director of the Cancer Immunotherapy Program (DITEP) at Gustave Roussy. His specialisms are immuno-oncology, early-phase immunotherapy, MSI-high tumours and intratumoural therapy, with a focus on PD-1 and immune checkpoint inhibitors. He was lead author of the KEYNOTE-158 analysis in the Journal of Clinical Oncology, which reported the efficacy of pembrolizumab in non-colorectal cancers with high microsatellite instability or mismatch repair deficiency and supported the drug's tumour-agnostic approvals. He now leads early-phase immunotherapy trials at DITEP and works on delivering immunotherapy directly into tumours. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Clinical Director, Cancer Immunotherapy Program (DITEP), Gustave Roussy
- Specialisms: Immuno-oncology; Early-phase immunotherapy; MSI-high tumours; Intratumoural therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Marabelle%20A%5BAuthor%5D%20pembrolizumab

## Connected records

- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/)
- terms: [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/)
- ideas: [Treat immunotherapy side-effects without wiping out the response](https://onco.cc/ideas/idea-bio2-steroid-sparing-irae/)
- key papers: [KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer](https://onco.cc/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/)

---
JSON: https://onco.cc/api/v1/entities/aurelien-marabelle.json